Rotigotine transdermal patch in combination therapy for Parkinson’s disease – observations in routine clinical practice

References

• Schapira AHV, Emre M, Jenner P, et al. Levodopa in the treatment of Parkinson’s disease. Eur J Neurol 2009;16:982-9
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91
   PubMed Web of Science ®Google Scholar
• Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 2005;252(Suppl 4):37-42
   Google Scholar
• Stocchi F. Dopamine receptor agonists in the treatment of advanced Parkinson’s disease. Parkinsonism Relat Disord 2009;15S:S54-7
   Google Scholar
• Talati R, Baker WL, Patel AA, et al. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysis. Int J Clin Pract 2009;63:613-23
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson’s disease. Parkinsonism Relat Disord 2009;15S:S44-53
   Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007;30:256-65
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
   PubMed Web of Science ®Google Scholar
• Neupro transdermal patch. Package Label. Available at: http://www.fachinfo.de/data/fi/jsearch?praep (Last accessed 18 May 2011)
   Google Scholar
• Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002;73:629-35
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al. eds. Recent Developments in Parkinson’s Disease, Vol. 2. Florham Park: MacMillan Healthcare Information, 1987:153-63
   Google Scholar
• Guidelines of the German Neurological Society (Leitlinien für Diagnostik und Therapie in der Neurologie; in German). Available at: http://www.uni-duesseldorf.de/AWMF/ll/030-010.htm (Last accessed 18 May 2011)
   Google Scholar
• Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord 2004;19:513-17
   PubMed Web of Science ®Google Scholar
• Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005;20:1502-7
   PubMed Web of Science ®Google Scholar
• Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24:826-32
   PubMed Web of Science ®Google Scholar
• Setter SM. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease. Neurol Clin 2008;26:S45-63
   PubMed Web of Science ®Google Scholar
• Grosset D, Grosset K, Emmermann A, et al. Improved self-reported compliance with transdermal (patch) versus oral medication in Parkinson’s disease patients. Eur J Neurol 2006;13(Suppl 2):88-9 (abstract P1175)
   Google Scholar
• Schnitzler A, Leffers K-W, Häck H-J. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s disease. Parkinsonism Relat Disord 2010;16:513-16
   PubMed Web of Science ®Google Scholar
• Miller N, Allcock L, Hildreth AJ, et al. Swallowing problems in Parkinson disease: frequency and clinical correlates. J Neurol Neurosurg Psychiatry 2009;80:1047-9
   PubMed Web of Science ®Google Scholar
• Plowman-Prine EK, Sapienza CM, Okun MS, et al. The relationship between quality of life and swallowing in Parkinson’s disease. Mov Disord 2009;24:1352-8
   PubMed Web of Science ®Google Scholar
• Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 1988;11:512-19
   PubMed Web of Science ®Google Scholar
• Giladi N, Fichtner A, Poewe W, et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm 2010;117:1395-9
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95
   PubMed Web of Science ®Google Scholar